On Thursday, April 10, 2025, four representatives from Bristol Myers Squibb Japan visited the CCII: Mr. Hide Katsuma, President and Representative Director, Mr. Yoshihide Oba, Executive Officer, Head of Innovative Medicines Business Unit, Ms. Shiwa Kan, Executive Director, Head of Commercialization Excellence and Mr. Koichi Tanimoto, Head of People Organization.

After a brief introduction about the CCII by Vice-Director Prof Fagarasan, each member presented the latest developments in research at CCII with a focus on potential applications in the medical and pharmaceutical fields.

The discussions focused on the potential for collaboration between BMS and CCII, particularly in the area of screening, and on longer-term, comprehensive collaborations, including the acceptance of employee training programs from BMS.

Bristol Myers Squibb Building of CCII, which was constructed with a substantial donation from BMS as its name suggests, was mentioned by President Katsuma as a symbolic representation of the company’s efforts to engage with academia. BMS and CCII agreed to continue holding discussions and further deepen their cooperative relationship moving forward.